We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aging Population Drives Healthcare Growth: Stocks to Watch
Read MoreHide Full Article
An updated edition of the July 6, 2026, article.
The world’s population is aging rapidly, reshaping how healthcare systems, corporations and investors approach long-term growth opportunities. According to the July 2026 data from the World Health Organization, 1.1 billion people globally were aged 60 years or older in 2023 and that number is projected to nearly double to 2.1 billion by 2050. By 2030, one in six people worldwide is expected to be aged 60 or older. Meanwhile, the number of people aged 80 years and older is projected to more than triple between 2023 and 2060, reaching 545 million.
This demographic transition continues to create a multitrillion-dollar healthcare opportunity. Fortune Business Insights estimates that the global geriatric care services market will grow from $1.24 trillion in 2025 to $2.16 trillion by 2034, reflecting a 6.4% CAGR. The company cites the growing elderly population, rising prevalence of chronic diseases and increasing demand for specialized and home-based care services as key factors driving market growth.
The aging population is significantly altering healthcare consumption patterns and creating growth opportunities across pharmaceuticals, diabetes care, robotic surgery, cardiovascular devices, obesity treatment, sleep health and digital monitoring technologies.
Healthcare companies such as AbbVie (ABBV - Free Report) , Tandem Diabetes Care (TNDM - Free Report) and Amgen Inc. (AMGN - Free Report) are well positioned across several of these areas. By enhancing operational efficiency, they are increasingly expanding their presence in the Seniors & Aging Demographics domain.
As longevity improves globally, age-related conditions such as obesity, cardiovascular disease, diabetes, sleep apnea, neurodegenerative disorders and musculoskeletal complications are becoming more prevalent. Digital health solutions, artificial intelligence-driven diagnostics and home-based monitoring systems are transforming elder care, creating new revenue opportunities for healthcare firms.
Notably, Stryker (SYK - Free Report) is advancing AI-enabled orthopedics through its Mako SmartRobotics platform, which combines 3D CT-based planning with technology designed to assist surgeons during joint replacement procedures. Boston Scientific (BSX - Free Report) is incorporating AI into its cardiovascular portfolio, including AI-powered Automated Lesion Assessment on its AVVIGO+ imaging platform, while advancing minimally invasive treatments such as its SEISMIQ intravascular lithotripsy system for complex coronary lesions.
From an investment perspective, healthcare continues to offer defensive characteristics during volatile economic environments. Demand for critical treatments, medical procedures and chronic disease therapies generally remains resilient regardless of macroeconomic cycles, supporting stable cash flows and long-term earnings visibility.
Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity.
3 Seniors & Aging Demographics Stocks in the Spotlight
AbbVie has been strengthening its position in aging-related healthcare through immunology and neuroscience. On Aug. 27, 2026, the company submitted a regulatory application to the European Medicines Agency for a subcutaneous induction option for SKYRIZI in adults with moderately to severely active Crohn’s disease, supported by Phase 3 AFFIRM data. AbbVie also secured European Commission approvals for RINVOQ in severe alopecia areata and non-segmental vitiligo in July. In June, it announced a proposed acquisition of Apogee Therapeutics to deepen its immunology portfolio. The stock currently carries a Zacks Rank #3 (Hold).
Tandem Diabetes Care is advancing automated and connected diabetes management, an increasingly important area as chronic disease prevalence rises with age. In August 2026, the company reported second-quarter sales of $254.6 million and highlighted FDA clearance and CE Mark approval for Control-IQ+ automated insulin delivery in people with type 1 diabetes during pregnancy, along with CE Mark approval for adults with type 2 diabetes. Tandem also expanded t X2 compatibility with Abbott’s FreeStyle Libre 3 Plus sensor to five international markets. The stock carries a Zacks Rank #3.
Amgen is expanding its presence in aging-related cardiovascular and metabolic care through Repatha and its investigational obesity therapy MariTide. On Aug. 31, 2026, Amgen reported that Repatha reduced the risk of all-cause mortality by 20% in more than 12,000 high-risk patients without a prior heart attack or stroke in a prespecified analysis of the Phase 3 VESALIUS-CV trial. Meanwhile, MariTide is being evaluated in Phase 3 studies for obesity and related conditions, including type 2 diabetes, heart failure, obstructive sleep apnea and atherosclerotic cardiovascular disease. The stock also carries a Zacks Rank #3.
View the Zacks #1 Rank List
Image: Bigstock
Aging Population Drives Healthcare Growth: Stocks to Watch
An updated edition of the July 6, 2026, article.
The world’s population is aging rapidly, reshaping how healthcare systems, corporations and investors approach long-term growth opportunities. According to the July 2026 data from the World Health Organization, 1.1 billion people globally were aged 60 years or older in 2023 and that number is projected to nearly double to 2.1 billion by 2050. By 2030, one in six people worldwide is expected to be aged 60 or older. Meanwhile, the number of people aged 80 years and older is projected to more than triple between 2023 and 2060, reaching 545 million.
This demographic transition continues to create a multitrillion-dollar healthcare opportunity. Fortune Business Insights estimates that the global geriatric care services market will grow from $1.24 trillion in 2025 to $2.16 trillion by 2034, reflecting a 6.4% CAGR. The company cites the growing elderly population, rising prevalence of chronic diseases and increasing demand for specialized and home-based care services as key factors driving market growth.
The aging population is significantly altering healthcare consumption patterns and creating growth opportunities across pharmaceuticals, diabetes care, robotic surgery, cardiovascular devices, obesity treatment, sleep health and digital monitoring technologies.
Healthcare companies such as AbbVie (ABBV - Free Report) , Tandem Diabetes Care (TNDM - Free Report) and Amgen Inc. (AMGN - Free Report) are well positioned across several of these areas. By enhancing operational efficiency, they are increasingly expanding their presence in the Seniors & Aging Demographics domain.
As longevity improves globally, age-related conditions such as obesity, cardiovascular disease, diabetes, sleep apnea, neurodegenerative disorders and musculoskeletal complications are becoming more prevalent. Digital health solutions, artificial intelligence-driven diagnostics and home-based monitoring systems are transforming elder care, creating new revenue opportunities for healthcare firms.
Notably, Stryker (SYK - Free Report) is advancing AI-enabled orthopedics through its Mako SmartRobotics platform, which combines 3D CT-based planning with technology designed to assist surgeons during joint replacement procedures. Boston Scientific (BSX - Free Report) is incorporating AI into its cardiovascular portfolio, including AI-powered Automated Lesion Assessment on its AVVIGO+ imaging platform, while advancing minimally invasive treatments such as its SEISMIQ intravascular lithotripsy system for complex coronary lesions.
From an investment perspective, healthcare continues to offer defensive characteristics during volatile economic environments. Demand for critical treatments, medical procedures and chronic disease therapies generally remains resilient regardless of macroeconomic cycles, supporting stable cash flows and long-term earnings visibility.
Ready to uncover more transformative thematic investment ideas? Explore 30 cutting-edge investment themes with Zacks Thematic Screens and discover your next big opportunity.
3 Seniors & Aging Demographics Stocks in the Spotlight
AbbVie has been strengthening its position in aging-related healthcare through immunology and neuroscience. On Aug. 27, 2026, the company submitted a regulatory application to the European Medicines Agency for a subcutaneous induction option for SKYRIZI in adults with moderately to severely active Crohn’s disease, supported by Phase 3 AFFIRM data. AbbVie also secured European Commission approvals for RINVOQ in severe alopecia areata and non-segmental vitiligo in July. In June, it announced a proposed acquisition of Apogee Therapeutics to deepen its immunology portfolio. The stock currently carries a Zacks Rank #3 (Hold).
Tandem Diabetes Care is advancing automated and connected diabetes management, an increasingly important area as chronic disease prevalence rises with age. In August 2026, the company reported second-quarter sales of $254.6 million and highlighted FDA clearance and CE Mark approval for Control-IQ+ automated insulin delivery in people with type 1 diabetes during pregnancy, along with CE Mark approval for adults with type 2 diabetes. Tandem also expanded t X2 compatibility with Abbott’s FreeStyle Libre 3 Plus sensor to five international markets. The stock carries a Zacks Rank #3.
Amgen is expanding its presence in aging-related cardiovascular and metabolic care through Repatha and its investigational obesity therapy MariTide. On Aug. 31, 2026, Amgen reported that Repatha reduced the risk of all-cause mortality by 20% in more than 12,000 high-risk patients without a prior heart attack or stroke in a prespecified analysis of the Phase 3 VESALIUS-CV trial. Meanwhile, MariTide is being evaluated in Phase 3 studies for obesity and related conditions, including type 2 diabetes, heart failure, obstructive sleep apnea and atherosclerotic cardiovascular disease. The stock also carries a Zacks Rank #3.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.